Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime
- 20 October 2016
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 64 (2) , 116-123
Abstract
Background Recent evidence suggests that among patients receiving vancomycin, receipt of concomitant piperacillin/tazobactam increases the risk of nephrotoxicity. Well controlled, adequately powered studies comparing rates of acute kidney injury (AKI) among patients receiving vancomycin + piperacillin/tazobactam (VPT) compared to similar patients receiving vancomycin + cefepime (VC) are lacking. This study compared the incidence of AKI among patients receiving combination therapy with VPT to a matched group of patients receiving VC. Methods A retrospective matched cohort study was performed. Patients were eligible if they received combination therapy with either VC or VPT for ≥ 48 hours. Patients were excluded if their baseline serum creatinine was >1.2mg/dl or they were receiving renal replacement therapy. Patients receiving VC were matched to patients receiving VPT based on severity of illness, ICU status, duration of combination therapy, vancomycin dose and number of concomitant nephrotoxins. The primary outcome was the incidence of RIFLE criteria-defined AKI. Multivariate modeling was performed using Cox proportional hazards. Results 558 patients were included. The mean age was 55.9±16.6 years. AKI rates were significantly higher in the VPT than the VC group (81/279 (29%) vs. 31/279 (11%).) In multivariate analysis, therapy with VPT was an independent predictor for AKI (HR=4.27, 95% CI 2.73-6.68). Among patients who developed AKI, the median onset was more rapid in the VPT compared to the VC group (3 vs. 5 days, p=Conclusion The VPT combination was associated with both an increased AKI risk and a more rapid onset of AKI, compared to the VC combination.Keywords
This publication has 12 references indexed in Scilit:
- Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial StewardshipAntimicrobial Agents and Chemotherapy, 2016
- Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin‐Tazobactam or Cefepime: A Retrospective Cohort StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Prevalence of Antimicrobial Use in US Acute Care Hospitals, May-September 2011JAMA, 2014
- Comparison of the Incidence of Vancomycin‐Induced Nephrotoxicity in Hospitalized Patients with and without Concomitant Piperacillin‐TazobactamPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Comparison of Acute Kidney Injury During Treatment with Vancomycin in Combination with Piperacillin‐Tazobactam or CefepimePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012Intensive Care Medicine, 2013
- Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases PharmacistsClinical Infectious Diseases, 2009
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) GroupCritical Care, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987